Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: Major implications for the detection of partly deficient patients

British Journal of Cancer

Volumn 79, Issue 3-4, 1999, Pages 620-626

  Van Kuilenburg, A B P ^a,c   Van Lenthe, H ^a   Blom, M J ^a   Mul, E P J ^b   Van Gennip, A H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

5 Fluorouracil; Blood cells; Cancer; Dihydropyrimidine dehydrogenase; Patients

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ADULT; AGED; ARTICLE; BLOOD CELL; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEFICIENCY; ERYTHROCYTE; FEMALE; GRANULOCYTE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LYMPHOCYTE; MALE; MONOCYTE; PRIORITY JOURNAL; THROMBOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELLS; CARCINOMA, RENAL CELL; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; OXIDOREDUCTASES; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 0032956515     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690097     Document Type: Article

References (50)

1. Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC, Grochow LB, Sartorius SE, Noc DA, Hohneker JA and Rowinsky EK (1996) Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 14: 3085-3096
2. Beuzeboc P, Pierga J-Y, Stoppa-Lyonnet D, Etienne MC, Milano G and Pouillart P (1996) Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta. Eur J Cancer 32A: 370-371
3. Born J, Hansen K, Mölle M and Fehm H-L (1997) Effect of sleep and circadian rhythm on human circulating immune cells. J Immunol 158: 4454-4464
4. Chazal M, Etienne MC, Renée N, Bourgeon A, Richelme H and Milano G (1996) Link between dihydropyrimidine dehyrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res 2: 507-510
5. Daher GC, Naguib FNM, el Kouni MH, Zhang R, Soong SJ and Diasio RB (1991) Inhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil. Biochem Pharmacol 41: 1887-1893
6. De Boer M and Roos D (1986) Metabolic comparison between basophils and other leukocytes from human blood. J Immunol 136: 3447-3454
7. De Korte D, Haverkort WA, Van Gennip AH and Roos D (1985) Nucleotide profiles of normal blood cells determined by high-performance liquid chromatography. Anal Biochem 147: 197-209
8. Diasio RB, Beavers TL and Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase, biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81: 47-51
9. Diasio RB, Lu Z, Zhang R and Shahinian HS (1995) Fluoropyrimidine catabolism. Cancer Treatment Res 78: 71-93
10. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renée N, Schneider M, Demard F and Milano G (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12: 2248-2253
11. Fernandez-Salguero P, Gonzalez FJ, Etienne MC, Milano G and Kimura S (1995) Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes. Biochem Pharmacol 50: 1015-1020
12. Fleming RA, Milano G, Thyss A, Etienne M-C, Renée N, Schneider M and Demard F (1992) Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52: 2899-2902
13. Fleming RA, Milano GA, Gaspard MH, Bargnoux PJ, Thyss A, Plagne R, Reneé M, Schneider M and Demard F (1993) Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 29A: 740-744
14. Grem JL, Yee LK, Venzon DJ, Takimoto CH and Allegra CJ (1997) Inter-and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother Pharmacol 40: 117-125
15. Harris BE, Song R, Soong S-J and Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197-201
16. Harris BE, Carpenter JT and Diasio RB (1991) Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. Cancer 68: 499-501
17. Haus E (1992) Chronobiology of circulating blood cells and platelets. In Biologic Rhythms in Clinical and Laboratory Medicine. Touitou Y and Haus E (eds.), pp. 504-526. Springer Verlag: New York
18. Heggie GD, Sommadossi J-P, Cross DS, Huster WJ and Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolism in plasma, urine, and bile. Cancer Res 47: 2203-2206
19. Ho DH, Townsend L, Luna MA and Bodey GP (1986) Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 6: 781-784
20. Houyau P, Gay C, Chatelut E, Canal P, Roché H and Milano G (1993) Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J Natl Cancer Inst 85: 1602-1603
21. Kaffenberger W, Hölzer-Müller L, Auberger T, Clasen BPE, Hohlmeier G and Van Beuningen D (1995) An immunological outcome predictive score for head and neck carcinoma patients. Strahlenther Onkol 171: 444-453
22. Lu Z, Zhang R and Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53: 5433-5438
23. Lyss AP, Lilenbaum RC, Harris BE and Diasio RB (1993) Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest 11: 239-240
24. Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, Wexler LH, Adde MA, McClure LL and Gress RE (1994) Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 84: 2221-2228
25. Maldonado JE and Hanlon DG (1965) Monocytosis: a current appraisal. Mayo Clin Proc 40: 248-259
26. McMurrough J and McLeod HL (1996) Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol 41: 425-427
27. Meinsma R, Fernandez-Salguero P, Van Kuilenburg ABP, Van Gennip AH and Gonzalez FJ (1995) Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uraciluria. DNA Cell Biol 14: 1-6
28. Milano G and Etienne MC (1994a) Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil. Anticancer Res 14: 2295-2298
29. Milano G and Etienne MC (1994b) Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics 4: 301-306
30. Naguib FNM, el Kouni MH and Cha S (1985) Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45: 5405-5412
31. Pero RW, Johnson D and Olsson A (1984) Catabolism of exogenously supplied thymidine to thymine and dihydrothymine by platelets in human peripheral blood. Cancer Res 44: 4955-4961
32. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85
33. Spector T, Harrington JA and Porter DJT (1993) 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 46: 2243-2248
34. Stéphan F, Etienne MC, Wallays C, Milano G and Clergue F (1995) Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Am J Med 99: 685-688
35. Strender LE, Blomgren H, Petrini B, Wasserman J, Forsgren M, Norberg R, Baral E and Wallgren A (1981) Immunological monitoring in breast cancer patients receiving postoperative adjuvant chemotherapy. Cancer 48: 1996-2002
36. Takamoto CH, Lu Z-H, Zhang R, Liang MD, Larson LV, Cantilena Jr LR, Grem JL, Allegra CJ, Diasio RB and Chu E (1996) Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 2: 477-481
37. Tuchman M, Stoeckeler JS, Kiang DT, O'Dea RF, Ramnaraine ML and Mirkin BL (1985) Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 313: 245-249
38. Van Gennip AH, Busch S, Elzinga L, Stroomer AEM, Van Cruchten A, Scholten EG and Abeling NGGM (1993) Application of simple chromatographic methods for the diagnosis of defects in pyrimidine degradation. Clin Chem 39: 380-385
39. Van Gennip AH, Abeling NGGM, Stroomer AEM, Van Lenthe H and Bakker HD (1994) Clinical and biochemical findings in six patients with pyrimidine degradation defects. J Inherited Metab Dis 17: 130-132
40. Van Gennip AH, Abeling NGGM, Vreken P and Van Kuilenburg ABP (1997) Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects. J Inherited Metab Dis 20: 203-213
41. Van Kuilenburg ABP, Van Lenthe H and Van Gennip AH (1996) Identification and tissue-specific expression of a NADH-dependent activity of dihydropyrimidine dehydrogenase in man. Anticancer Res 16: 389-394
42. Van Kuilenburg ABP, Vreken P, Beex LVAM, Meinsma R, Van Lenthe H, De Abreu RA and Van Gennip AH (1997a) Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur J Cancer 33: 2258-2264
43. Van Kuilenburg ABP, Van Lenthe H, Wanders RJA and Van Gennip AH (1997b) Subcellular localization of dihydropyrimidine dehydrogenase. Biol Chem 378: 1047-1053
44. Van Kuilenburg ABP, Vreken P, Beex LVAM, Meinsma R, Van Lenthe H, De Abreu RA and Van Gennip AH (1998a) Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Adv Exp Med Biol 431: 293-298
45. Van Kuilenburg ABP, Van Lenthe H, Wanders RJA and Van Gennip AH (1998b) Subcellular localization of dihydropyrimidine dehydrogenase. Adv Exp Med Biol 431: 817-821
46. Van Kuilenburg ABP, Poorter RL, Peters GJ, Van Gennip AH, Van Lenthe H, Stroomer AEM, Smid K, Noordhuis P, Bakker PJM and Veenhof CHN (1998c) No circadian variation of dihydropyrimidine dehydrogenase, uridine phosphorylase. β-alanine and 5-fluorouracil during continuous infusion of 5-fluorouracil. Adv Exp Med Biol 431: 811-816
47. Vreken P, Van Kuilenburg ABP, Meinsma R, Smit GPA, Bakker HD, De Abreu RA and Van Gennip AH (1996) A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherited Metab Dis 19: 645-654
48. Vreken P, Van Kuilenburg ABP, Meinsma R and Van Gennip AH (1997a) Identification of novel point mutations in the dihydropyrimidine dehydrogenase gene. J Inherited Metab Dis 20: 335-338
49. Vreken P, Van Kuilenburg ABP, Meinsma R, De Abreu RA and Van Gennip AH (1997b) Identification of a four-base deletion (delTCAT296-299) in the dihydropyrimidine dehydrogenase gene with variable clinical expression. Hum Genet 100: 263-265
50. Wei X, McLeod HL, McMurrough J, Gonzalez FJ and Fernandez-Salguero P (1996) Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 3: 610-615